Core Viewpoint - The FDA has lifted the clinical hold on Intellia Therapeutics' IND for the MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) [1] Group 1: Trial Details - The trial's target enrollment has been increased from approximately 50 patients to approximately 60 patients [3] - The primary endpoints of the study include a change in modified neuropathy impairment score and a change in serum TTR levels [3] - Long-term follow-up data from the ongoing Phase 1 study indicates a mean serum TTR reduction of 92% at 24 months for patients receiving a one-time dose of 0.3 mg/kg or higher [4] Group 2: Safety and Regulatory Updates - The clinical holds on the INDs for MAGNITUDE and MAGNITUDE-2 were imposed in October 2025 due to safety concerns related to liver transaminases and bilirubin levels [5] - Intellia is in ongoing discussions with the FDA regarding the clinical hold on the IND for the MAGNITUDE Phase 3 trial for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) [6] Group 3: Analyst Insights - Analysts express belief in the efficacy of Intellia's platform, noting that 2026 will be significant for the HAE program, but safety events related to nex-z may continue to impact stock performance until regulatory clarity is achieved [7] - Analyst Myles Minter maintains a Market Perform rating on Intellia, showing increased optimism regarding a regulatory path forward for the company's platform [7] Group 4: Market Reaction - NTLA stock has increased by 9.53%, reaching $15.28 [8]